Days after suffering an earnings setback, a company should not expect its share price to scale record heights. But a Chinese maker of novel cancer drugs has done just that, defying conventional market logic.
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. (6990.HK) reported on August 18 that its revenues fell 31.3% to 950 million yuan ($132.72 million) in the first half of 2025 from the same period a year earlier, swelling its net loss to 145 million yuan.
But over the following days the drug developer’s share price climbed to a record high, pushing its market value above the HK$100 billion ($12.8 billion) mark and landing Kelun-Biotech in the top tier of innovative drug companies listed in Hong Kong.
您已阅读12%（709字），剩余88%（5146字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。